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Abstract 
 
Both glucocorticoids and selective serotonin reuptake inhibitors (SSRIs) alter aspects of 5-HT function 
including somatodendritic 5-HT1A autoreceptor sensitivity.  Many depressed patients prescribed SSRIs 
have pre-existing flattened diurnal gluococorticoid rhythm.  In these patients, interactions between 
flattened glucocorticoid rhythm and chronic SSRIs, which impact on the SSRI’s ability to elevate 
forebrain 5-HT, may alter clinical efficacy. 
 
To address this issue rats underwent implantation of slow-release corticosterone (75 mg pellet s.c.) (to 
flatten the glucocorticoid rhythm) or sham surgery, and injection of fluoxetine (10 mg/kg/day i.p., 12 
days) or vehicle.  Using microdialysis in the frontal cortex we found that (21 h after the last injection), 
extracellular 5-HT was elevated in fluoxetine, or corticosterone treated animals, but not in those 
treated with corticosterone plus fluoxetine.  In fluoxetine treated animals, blockade of terminal 
reuptake by local perfusion of fluoxetine, increased 5-HT to the same level as it did in controls, 
suggesting normal terminal 5-HT release after chronic fluoxetine.  However, 5-HT levels following 
local reuptake blockade in both the corticosterone and corticosterone plus fluoxetine groups, were 
lower than controls suggesting a corticosterone-induced decrease in terminal release.  Finally in 
fluoxetine, corticosterone, and corticosterone plus fluoxetine groups there was marked 5-HT1A 
receptor desensitisation, evidenced by attenuation of the decrease in 5-HT release following systemic 
fluoxetine injection. 
 
The data indicate that, despite desensitisation of 5-HT1A autoreceptors, concurrent flattened 
glucocorticoid rhythm compromises the ability of SSRIs to elevate forebrain 5-HT.  These findings 
suggest a potential mechanism for the reduced antidepressant efficacy of SSRIs in those patients with 
pre-existing glucocorticoid abnormalities. 
 
Keywords: antidepressant; glucocorticoid; selective serotonin reuptake inhibitor (SSRI); serotonin, 
5-hydroxytryptamine (5-HT); in vivo microdialysis; 5-HT1A autoreceptor 
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Introduction 
 
An increase in synaptic levels of 5-HT in the forebrain may be necessary for the therapeutic efficacy 
of antidepressant drugs including selective serotonin reuptake inhibitors (SSRIs) (see Blier, 2001).  
However, pharmacological studies indicate that SSRIs acutely inhibit 5-HT release by increasing 
activation of somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) and that this 
effect limits their ability to increase synaptic 5-HT in the forebrain (Gartside et al., 1995; Hjorth and 
Auerbach, 1996).  On chronic administration, SSRIs have been shown to desensitise 5-HT1A 
autoreceptors (De Montigny et al., 1990; Le Poul et al., 1995; Davidson and Stamford, 1998).  This 
desensitisation, which allows levels of synaptic 5-HT in forebrain to rise (Gardier et al., 1996; Dawson 
et al., 2000), shows some temporal correspondence with the onset of antidepressant efficacy (Gardier 
et al., 1996; Le Poul et al., 1995) and hence is accepted to be an important feature of the response to 
chronic administration of SSRIs (see Blier et al., 1987, Blier, 2001; Artigas et al., 2001). 
 
Somatodendritic 5-HT1A autoreceptors are subject to regulation, not only by chronic SSRI 
administration, but also by glucocorticoids (cortisol in man, and corticosterone in rodents) (Young et 
al. 1994; Laaris et al. 1997).  This may be of particular importance since, in addition to abnormalities 
of 5-HT function (Drevets et al., 2000; Sargent et al., 2000; Bhagwagar et al., 2002), many depressed 
patients display abnormal hypothalamo-pituitary adrenal (HPA) axis function.  This is manifest in a 
flattening of the normal diurnal rhythm of glucocorticoid levels together with an elevation of nadir 
levels (Deuschle et al., 1997; Wong et al., 2000).  We have recently shown in rats, that flattening the 
glucocorticoid rhythm, with an elevation of the nadir, causes a desensitisation of somatodendritic 
5-HT1A autoreceptors (Leitch et al., 2003).  Hence the response of 5-HT1A receptors to flattened 
glucocorticoid rhythm in some part resembles their response to SSRIs.  Indeed it has been suggested 
hence the HPA axis changes observed in depression may represent a ‘natural antidepressant response’ 
(Young, 1994).  However, corticosterone has also been shown in previous studies to regulate 5-HT 
synthesis (Rastogi and Singhal, 1978; Miller et al., 1980; Culman et al., 1984) and may have other 
effects on 5-HT neurotransmission (see Chaouloff, 2000). 
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Given that both altered glucocorticoid rhythm and chronic SSRI treatment have been shown to alter 
components of 5-HT neurotransmission including 5-HT1A autoreceptor sensitivity it seems possible 
that these two factors may interact.  Any such interaction may have the result of either enhancing or 
attenuating the ability of SSRIs to elevate forebrain 5-HT and hence may affect antidepressant 
efficacy.  Since many depressed patients with a pre-existing flattening of their glucocorticoid rhythm 
will be prescribed SSRIs as a treatment for their depression this potential interaction may be of 
therapeutic importance.   
 
The present study was designed to examine whether the actions of chronic fluoxetine on 5-HT 
function may be modified by the concurrent presence of flattened glucocorticoid rhythm.  Specifically 
we examined effects of the two treatments, alone and in combination, on the sensitivity of 5-HT1A 
receptors controlling 5-HT release in the frontal cortex and on extracellular levels of 5-HT in this 
region.  In adrenally-intact male rats we used slow release corticosterone pellets in a paradigm which 
we have previously shown to flatten the glucocorticoid rhythm without increasing total glucocorticoid 
exposure (Leitch et al., 2003).  We combined this corticosterone treatment (or sham surgery) with 
chronic once daily injection of the SSRI fluoxetine (or vehicle).  Following two weeks’ treatment, 
aspects of brain 5-HT neurotransmission were examined using in vivo microdialysis. 
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Methods 
Animals 
Male Sprague-Dawley rats purchased from Bantin and Kingman, UK, were group housed with ad 
libitum access to food and water under controlled environmental conditions (temperature: 20 C, 
humidity: 30 %-50 %), on a 12 h light/dark cycle (lights on 7 a.m.).  Animals were allowed to 
acclimatize for 1 week before undergoing any procedures.  This study was carried out in accordance 
with the UK Animals (Scientific Procedures) Act. 
 
Chronic treatments 
Groups of rats underwent implantation of a corticosterone pellet or sham surgery and chronic injection 
of fluoxetine or vehicle.  Rats (approx. 180 g) were implanted with commercially made corticosterone 
pellets (Innovative Research of America, USA) designed to release 3.6 mg/day corticosterone.  Under 
isoflurane anaesthesia pellets were implanted subcutaneously on the right flank and the wound was 
sutured.  Immediately following surgery the analgesic buprenorphine (0.05 mg/kg s.c.) was 
administered.  Sham rats underwent the same surgical procedure but no pellet was implanted.   
 
Following surgery rats were housed in groups of two or three.  Two days following surgery chronic 
injections were commenced.  Rats were weighed every second day and injected i.p. daily at around 1 
pm with of fluoxetine (10 mg/kg i.p. in sterile water) or water vehicle (1 ml/kg body weight). 
 
Microdialysis 
On day 13 or 14 following surgery (i.e. 11 or 12 days following commencement of chronic daily 
injections) animals underwent microdialysis under chloral hydrate anaesthesia as described elsewhere 
(Gartside et al., 1995).  Briefly, rats were anaesthetised with chloral hydrate and a concentric 
microdialysis probe with a 3-3.5 mm dialysing window (Hospal membrane) was stereotaxically 
implanted into the right frontal cortex (stereotaxic co-ordinates: rostral 3.2 mm, lateral 3.0 mm, ventral 
-4.6 mm from bregma and dura surface, with the incisor bar set 3.3 mm below the interaural line).  Co-
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ordinates were adjusted for animals under 220 g and probe placement was verified post hoc by 
inspection of coronal brain sections.   
 
The dialysis probe was continuously perfused at 2.3 l/min with artificial CSF (140 mM NaCl, 3 mM 
KCl, 2.5 mM CaCl2, 1 mM MgCl2, 1.2 mM Na2HPO4, 0.27 mM NaH2PO4, 7.2 mM glucose, pH 7.4).  
Dialysates collected over 20 minute periods were injected on to a high performance liquid 
chromatography (HPLC) system and separation was performed on a 100 mm x 4.6 mm 3 m 
microsorb 100 C18 HPLC column (Varian, USA) maintained at 30C using a column heater (Waters).  
Mobile phase (127 mM NaH2PO4, 25 M octane sulphonic acid, 0.045% EDTA, 15% methanol, pH 
3.9) was pumped through the system at 1.1 ml/min and 5-HT was detected using a Coulochem II (ESA 
Inc, USA) electrochemical detector fitted with a 5020 guard cell (E = 250 mV) and a 5014B 
microdialysis cell (E1 = 60 mV and E2 = 200 mV).  The resulting peak height was measured and 
quantified with reference to external standards containing 50 and 500 fmol 5-HT.  The lower limit of 
detection (2 x noise) of the HPLC assay for 5-HT was around 4 fmol. 
 
Once a stable baseline of dialysate 5-HT was established (2-3 h after implantation), the perfusion 
medium was switched to one containing 10 M fluoxetine and samples collected for a further 80 min.  
Rats were then injected with fluoxetine (10 mg/kg i.p.) and dialysates collected for a further 120 min.  
Groups of two or three rats from a single treatment group were used each day.  The microdialysis 
procedure was started at around 8:30 a.m. and fluoxetine was injected around 1 pm. 
 
Data Analysis and statistics 
Data shown are mean  s.e.m.  Time-course dialysate 5-HT data are presented as absolute amounts of 
5-HT in the dialysate.  The time-course of the response to systemic fluoxetine is also shown as change 
from pre-drug baseline (average of two pre-drug values).  Basal 5-HT was calculated from the mean of 
the 3 samples before switching the perfusion medium (samples 1, 2 and 3).  5-HT levels after local 
perfusion of fluoxetine were calculated from the mean of samples 7 and 8 - although fluoxetine was 
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given i.p. before sample 8 was collected its effects did not become apparent until sample 9 and 
samples 7 and 8 represented the maximum levels of 5-HT attained.  The area under (over) the curve 
for the response to systemic fluoxetine was calculated as the sum of the changes from baseline 
(samples 7 and 8) in the postdrug measurement period (samples 9-13).  Statistical analysis of these 
data was carried out using a two way ANOVA with fluoxetine and corticosterone as between subjects 
factors, with post-hoc Student’s t tests.  Significance at the 95 % level and above is reported. 
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Results 
 
General health indicators 
All animals appeared healthy throughout the treatment period.  Although corticosterone implanted 
animals lost some weight in the few days following surgery, thereafter their rate of weight gain was 
similar to that in the sham treatment groups.  On the day of the dialysis experiment, sham/vehicle and 
sham/fluoxetine animals (275.39.6 g (6) and 256.2+3.6 g (9), respectively) were heavier than both 
corticosterone/vehicle and corticosterone /fluoxetine treated groups ((206.07.6 g (8) and 225.612.5 
g (8), respectively). 
 
Effects of treatments on extracellular 5-HT in the frontal cortex 
Basal 5-HT 
Following implantation of the microdialysis probe into the frontal cortex, levels of 5-HT in the 
dialysates fell rapidly (data not shown) and attained relatively stable basal levels after 2-3 hours 
(Figure 1).  Basal levels of 5-HT were elevated in both the sham/fluoxetine and the cort/vehicle groups 
when compared to the sham/vehicle group.  In the cort/fluoxetine group the basal 5-HT level was 
intermediate between the high level in the sham/fluoxetine and the cort/vehicle groups and the lower 
level in the sham/vehicle group (Figure 1).  The basal 5-HT levels in the four treatment groups, 
calculated as the mean of the last three samples before switching the perfusion medium, are presented 
in Figure 2.  Statistical analysis of these data by two-way ANOVA revealed no significant main effect 
of either fluoxetine or corticosterone.  However, there was a significant interaction between fluoxetine 
and corticosterone (F1,27=7.7 p=0.01) and a post hoc Student’s t-test showed that 5-HT levels in both 
the sham/fluoxetine and the corticosterone/vehicle groups were significantly higher than in the 
sham/vehicle group. 
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Effect of local inhibition of 5-HT reuptake 
When the perfusion medium was switched to one containing 10 M fluoxetine, levels of 5-HT in the 
dialysates rose over the following 80-100 minutes (see Figure 1).  However, the new 5-HT level 
attained varied between the treatment groups.  Figure 3 shows the mean level in each of the four 
treatment groups calculated from the average of samples 7 and 8.  Local perfusion of fluoxetine raised 
5-HT levels to the same levels in the sham/vehicle group and the sham/fluoxetine group.  In the 
corticosterone/vehicle and the corticosterone/fluoxetine groups the levels of 5-HT also rose following 
local fluoxetine perfusion however, in both cases the levels attained were lower than those in the sham 
surgery groups (Figure3).  Statistical analysis of these data showed that there was a significant main 
effect of corticosterone (F1,27=5.2, p<0.05) but that there was no significant main effect of fluoxetine, 
and no corticosterone x fluoxetine interaction. 
 
5-HT1A autoreceptor function 
Following establishment of new baseline levels of 5-HT in the presence of locally perfused fluoxetine, 
systemic administration of fluoxetine (10mg/kg i.p.) reduced dialysate 5-HT (see Figures 1 and 4).  In 
sham/vehicle treated animals systemic fluoxetine cause a large decrease in dialysate 5-HT.  However, 
in both sham/fluoxetine treated and corticosterone/vehicle treated animals, this response to systemic 
fluoxetine was markedly attenuated compared to sham/vehicle controls.  In animals that had been 
treated with the combination of corticosterone and fluoxetine (corticosterone/fluoxetine) the response 
to systemic fluoxetine was also markedly attenuated.  In figure 5 the responses to systemic fluoxetine 
in the four groups is shown as area under the curve for the postdrug measurement period.  Analysis of 
variance of the AUC data showed a significant main effect of fluoxetine (F1,27=10.9; p=0.003) and a 
significant main effect of corticosterone (F1,27=6.5; p=0.017) but no significant interaction. 
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Discussion 
 
In the present study we investigated the effects of chronic fluoxetine and flattened corticosterone 
rhythm, and their possible interactions with respect to central 5-HT neurotransmission.  We found that 
chronic fluoxetine and flattened corticosterone rhythm both individually and in combination, markedly 
desensitised 5-HT1A autoreceptors.  However, the treatments differed substantially with respect to their 
net effects on 5-HT levels in the frontal cortex.  Thus chronic fluoxetine (sham/fluoxetine) treatment 
elevated basal extracellular 5-HT levels (measured 21 h after the last dose of fluoxetine) relative to 
sham/vehicle controls.  However, when terminal reuptake was further blocked by local perfusion of 
fluoxetine, 5-HT attained the same absolute level in sham/fluoxetine treated animals as in 
sham/vehicle treated controls suggesting that terminal 5-HT release was normal.  In animals with 
flattened corticosterone rhythm (corticosterone/vehicle), basal extracellular 5-HT was also elevated 
compared to sham/vehicle controls but there was no elevation of basal 5-HT in the 
corticosterone/fluoxetine treated group.  Furthermore, following local reuptake blockade the cortical 
5-HT levels attained in both corticosterone/vehicle and corticosterone/fluoxetine treated groups were 
markedly lower than those in the sham/vehicle (and sham/fluoxetine) controls, consistent with there 
being decreased terminal release in corticosterone treated animals.   
 
Chronic fluoxetine 
Our present data showing an elevation in basal dialysate 5-HT are in accord with previous in vivo 
microdialysis studies in which chronic treatment with fluoxetine has been reported to increase 
extracellular 5-HT in the frontal cortex (Rutter et al., 1994; Invernizzi et al., 1996).  Although basal 
5-HT was elevated approximately 21 h after the last of the chronic injections of fluoxetine, we found 
that local application of fluoxetine further increased dialysate 5-HT, suggesting that at this time 5-HT 
reuptake in the frontal cortex is not fully inhibited.  However, in the chronic fluoxetine treated animals 
the level of dialysate 5-HT attained following local perfusion of fluoxetine was similar to that attained 
in vehicle treated controls.  These latter data, which suggest that terminal 5-HT release and hence 
5-HT firing is normal(ized) in the frontal cortex of the chronic fluoxetine group after 12 days’ 
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treatment, are consistent with electrophysiological studies showing normalization of 5-HT firing after 
2 weeks’ fluoxetine treatment (Le Poul et al., 2000).   
 
When terminal 5-HT reuptake is blocked, systemic administration of SSRIs has been shown to inhibit 
5-HT release 5-HT via activation of 5-HT1A receptors (Hjorth and Auerbach, 1996).  Here we used this 
decrease in dialysate 5-HT as an index of 5-HT1A receptor sensitivity.  We observed that in the chronic 
fluoxetine treated (sham/fluoxetine) animals the magnitude of the inhibitory response to systemic 
fluoxetine was markedly diminished compared to that seen in the sham/vehicle treated controls.  This 
finding is consistent with chronic fluoxetine treatment having induced a functional desensitisation of 
5-HT1A autoreceptors and again is in line with previous reports (Le Poul et al., 1995; Invernizzi et al., 
1996). 
 
Flattened glucocorticoid rhythm 
Like chronic fluoxetine, chronic flattening of the glucocorticoid rhythm (by clamping levels at a point 
midway between the normal nadir and zenith (Leitch et al., 2003)) resulted in an increase in basal 
dialysate 5-HT.  Indeed the levels of 5-HT in corticosterone/vehicle group were very similar to those 
in the sham/fluoxetine group 21 h after the last injection.  However, when terminal 5-HT reuptake was 
blocked by local perfusion of fluoxetine, the level of dialysate 5-HT attained in the 
corticosterone/vehicle treated animals was significantly lower than that in either the sham/fluoxetine 
or the sham/vehicle group.  Finally, corticosterone treated animals showed evidence of a 5-HT1A 
receptor desensitisation, which was of the same degree of magnitude as that in chronic fluoxetine 
treated animals.  This is fully consistent with our own recent data in which we found that the 
8-OHDPAT-induced inhibition of 5-HT release was markedly reduced in animals treated with this 
regime of corticosterone (Leitch et al., 2003). 
 
The mechanism underlying the effects of flattening the glucocorticoid rhythm on basal 5-HT is not 
clear but would be consistent with either a decrease in reuptake and/or an increase in terminal 5-HT 
release.  There are few data available on the effects of glucocorticoids on the 5-HT transporter but 
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what evidence is available suggests that flattened glucocorticoid rhythm is unlikely to decrease 5-HT 
reuptake (Kulikov et al., 1997; Fernandez et al., 2001).  An increase in 5-HT release is possible 
however it is unlikely that this is secondary to the 5-HT1A receptor desensitisation as pharmacological 
blockade of these receptors with WAY100635 has been shown to have no effect on 5-HT levels in 
frontal cortex dialysates (Gartside et al., 1995; Sharp et al., 1997; Invernizzi et al., 1996).  A more 
likely mechanism underlying increased 5-HT release would be an increase in the activity of tryptophan 
hydroxylase, an enzyme which has previously been shown to be increased by high corticosterone and 
stress (Rastogi and Singhal, 1978; Culman et al., 1984).  Whatever the mechanism of this increase in 
basal 5-HT, this effect of corticosterone is difficult to reconcile with the reduction in absolute 5-HT 
levels when terminal 5-HT reuptake was blocked.  One possibility is that the corticosterone treatment 
increases 5-HT synthesis and release but, at the same time, increases the sensitivity of terminal 5-HT1B 
autoreceptors.  Evidence suggests that the negative influence of 5-HT1B autoreceptors on 5-HT release 
is only manifest when synaptic levels are relatively high (Sharp et al., 1997; Roberts et al., 1999).  
Hence, in corticosterone treated animals increased 5-HT1B sensitivity could limit release when 
terminal reuptake is blocked whilst having no effect on (lower) basal levels.  The effects of 
glucocorticoids on the function of 5-HT1B terminal autoreceptors (as opposed to postsynaptic 5-HT1B 
receptors), has not to our knowledge been reported.  Although corticosteroids have been shown to be 
without influence on 5-HT1B receptor mRNA expression in the DRN (Neumaier et al., 2000), changes 
in 5-HT1B receptor function downstream of transcription are possible.  
 
Interaction between flattened glucocorticoid rhythm and chronic fluoxetine 
A key part of the present study was to examine the interactions between flattened corticosterone 
rhythm and chronic fluoxetine.  We found that, the combination of flattened glucocorticoid rhythm 
and chronic fluoxetine (corticosterone/fluoxetine) caused desensitization of 5-HT1A autoreceptors.  
Indeed, the combined treatment was if anything slightly more effective than either treatment alone.  
Although we found no statistical evidence for an interaction between the two treatments, this is most 
likely to be due to the magnitude of the desensitization to either treatment alone being near maximal 
and does not necessarily suggest that SSRIs and flattened corticosterone rhythm desensitise 5-HT1A 
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receptors via the same molecular mechanism.  In this respect it is perhaps of note that Le Poul et al. 
(1997) showed that the mechanism by which fluoxetine causes desensitisation of 5-HT1A receptors is 
independent of its ability to cause acute corticosterone release.  
 
In examining the interaction between flattened corticosterone rhythm and chronic fluoxetine, our most 
striking finding was that a concurrent flattened glucocorticoid rhythm decreased the ability of chronic 
fluoxetine to elevate forebrain 5-HT.  This was evidenced by the fact that 5-HT levels in the 
corticosterone/fluoxetine group were lower than those in the sham/fluoxetine group both when 5-HT 
reuptake was only partially blocked (21h after last fluoxetine injection), and when it was maximally 
blocked (after local perfusion of fluoxetine).  It is unclear how corticosterone brings about this effect 
although, as discussed above, flattened glucocorticoid rhythm may have effects on 5-HT synthesis 
and/or 5-HT autoreceptors.  Whatever the precise molecular effects of glucocorticoids it is apparent 
that in animals with flattened glucocorticoid rhythm the ability of chronic fluoxetine to elevate 
synaptic 5-HT levels is attenuated even though 5-HT1A receptors are effectively desensitized.   
 
Conclusions 
An elevation in synaptic 5-HT levels in the forebrain is proposed to underlie the antidepressant 
response to SSRIs (see Blier, 2001).  Interestingly, it was recently reported that upwards of 75% 
transporters are occupied at clinically effective doses of SSRIs (Meyer et al., 2001).  At baseline (i.e. 
21 h after the last fluoxetine injection) it seems probable that reuptake blockade was only partial 
however, blockade was probably close to maximal following local perfusion of fluoxetine.  Hence the 
levels of 5-HT attained here following local reuptake blockade may be the most clinically relevant.  
Corticosterone alone caused an increase in basal 5-HT (which might have some antidepressant effect) 
however, levels remain much lower than those that may be achieved by (total) reuptake blockade.  
Importantly in animals with flattened glucocorticoid rhythm the maximum 5-HT levels achieved 
following reuptake blockade were significantly reduced.  The desensitisation of 5-HT1A autoreceptors 
may be crucial in allowing the effect of SSRIs on terminal 5-HT to be manifest however, the present 
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study provides evidence that, concurrent flattened glucocorticoid rhythm compromises the ability of 
an SSRI to elevate forebrain 5-HT, even in the presence of desensitized 5-HT1A autoreceptors. 
 
Flattened glucocorticoid rhythm with raised nadir, is seen in a significant proportion of depressed 
patients as well as in the elderly (Wong et al., 2000; Ferrari et al., 2001), and the present data suggest 
that in these individuals the antidepressant efficacy of SSRIs may be severely compromised.  Indeed 
our findings may explain the recent observation of limited efficacy of SSRIs in patients with abnormal 
HPA axis function (Young et al., 2000).  Tricyclic antidepressants unlike SSRIs are reported to alter 
glucocortcoid receptor function (Pepin et al., 1989).  Hence TCAs may be able to normalize 
gluococorticoid rhythm a property which may confer greater efficacy in depressed patients with 
glucocorticoid abnormalities.  Further investigations of the interplay between glucocorticoids and 
5-HT function in relation to antidepressants are clearly warranted. 
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 Figure 1.  Time course of the dialysis experiment in the 4 treatment groups.  Dialysates were collected 
at 20 min intervals.  Bar indicates switching of the perfusion medium to one containing 10M 
fluoxetine, arrow indicates the injection of 10 mg/kg fluoxetine (ip).  Open circles sham/vehicle group 
(n=6), closed circles sham/fluoxetine group (n=9), open squares corticosterone/vehicle group (n=8), 
closed squares corticosterone/fluoxetine group (n=8).  Data are mean  Error bars omitted for clarity 
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Figure 2.  Basal 5-HT levels in the 4 treatment groups.  Open columns show data from vehicle treated 
animals, and shaded columns show data from fluoxetine treated groups.  Data are the mean  sem 
calculated from the samples 1-3 (see Figure 1) * p<005, ** p<001, post hoc LSD test. 
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Figure 3.  5-HT levels in the 4 treatment groups after addition local application of fluoxetine.  Open 
columns show data from vehicle treated groups, and shaded columns show data from fluoxetine 
treated groups.  Data are the mean  sem calculated from the mean of samples 7 and 8 ** p<001 main 
effect of corticosterone treatment (ANOVA). 
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Figure 4.  Time-course of the response to systemic injection of fluoxetine in the 4 treatment groups.  
Data are expressed as change from the baseline (mean of samples 7 and 8) and are mean  sem. 
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Figure 5.  Response to systemic injection of fluoxetine in the 4 treatment groups  Data are the area 
under the curve calculated by summing the differences from baseline (mean of samples 7 and 8) in the 
post injection samples.  For statistical analysis see text. 
 
